Cutting-Edge Oncology Carrick Therapeutics is focused on developing first-in-class, targeted cancer treatments for aggressive and resistant tumors, presenting opportunities to collaborate with specialty oncology clinics and providers seeking innovative therapies.

Strong Industry Partnerships Recent collaborations with major pharmaceutical companies like Pfizer, Arvinas, and Menarini highlight Carrick’s credibility and open avenues for joint clinical initiatives and broader distribution partnerships.

Robust Funding & Growth With $95 million raised and strategic investments from Pfizer, Carrick is positioned for rapid development and commercialization, offering potential for sales expansion through early access programs and new product launches.

Targeting Breast Cancer The company’s focus on HR+ HER2- breast cancer, the most common subtype in women, creates opportunities to engage with oncologists and healthcare providers specializing in breast cancer management.

Innovative Technology Stack Leveraging advanced biotech and cloud-based technologies, Carrick provides scalable solutions and data-driven insights for personalized cancer treatments, enabling partnerships with digital health and research organizations.